Ocular Therapeutix(OCUL) - 2024 Q1 - Quarterly Results

Exhibit 99.1 "Ocular's excellent progress in 2024 has put the Company on track to becoming a leading retinal care company. We have substantially enriched the organization with the appointment of recognized leaders in retinal care and clinical development; have completed a successful financing of $325 million in gross proceeds from existing and new top-tier healthcare investors; and have progressed our Phase 3 program for AXPAXLI™ in wet AMD," said Pravin U. Dugel, MD, Executive Chairman, President and Chief ...